Xtandi vs Tagrisso
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Xtandi | US Tagrisso | |
|---|---|---|
| Generic name | enzalutamide | osimertinib |
| Drug class | Androgen Receptor Inhibitor | EGFR Tyrosine Kinase Inhibitor |
| Treats | Prostate cancer | EGFR-positive non-small cell lung cancer |
| Category | Oncology | Oncology |
| Manufacturer | Astellas/Pfizer | AstraZeneca |
| Year approved | 2012 | 2015 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $90M | — |
| Common side effects | Fatigue, Hot flashes, High blood pressure, Falls | Diarrhea, Rash, Dry skin, Lung inflammation |
Frequently asked questions
Is Xtandi or Tagrisso better?
Neither is universally "better." Xtandi (enzalutamide) and Tagrisso (osimertinib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Xtandi and Tagrisso?
Xtandi is a Androgen Receptor Inhibitor made by Astellas/Pfizer, while Tagrisso is a EGFR Tyrosine Kinase Inhibitor made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Xtandi has the larger estimated TV advertising budget of the two.